- PR Newswire•2 months agoAmgen And UCB Announce Submission Of Application For Investigational Osteoporosis Medication Romosozumab In Japan
THOUSAND OAKS, Calif. and BRUSSELS, Dec. 19, 2016 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that an application seeking marketing approval of romosozumab for the treatment of osteoporosis for those at high risk of fracture has been submitted for review to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Amgen and UCB are co-developing romosozumab worldwide, with development in Japan being led by Amgen Astellas BioPharma (AABP) K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.
- PR Newswire•3 months agoResults From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis
THOUSAND OAKS, Calif. and BRUSSELS, Nov. 12, 2016 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced results from the Phase 3 BRIDGE study showing that in men with osteoporosis, the investigational agent romosozumab resulted in significant bone mineral density (BMD) gains at the lumbar spine, total hip and femoral neck compared to placebo at six and 12 months. Although more common in women, osteoporosis is also a serious health issue for men.
- PR Newswire•3 months ago
ATLANTA, Nov. 10, 2016 /PRNewswire/ -- UCB, Inc. today announced 40 recipients of the 2016 UCB Family Epilepsy Scholarship, recognizing outstanding individuals affected by epilepsy who are pursuing higher ...
UCBJY : Summary for UCB ADR - Yahoo Finance
UCB SA (UCBJY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||35.96 - 36.01|
|52 Week Range||29.20 - 41.60|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||19.43|
|Dividend & Yield||0.63 (1.75%)|
|1y Target Est||N/A|